$435 Million Series C Pushes NewLimit’s Valuation to $3.1 Billion
On June 3rd Beijing time, longevity biotech startup NewLimit announced a $435 million Series C funding round. Led by Peter Thiel’s Founders Fund, the round saw continued participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners, along with new investors Thrive Capital, Greenoaks, and Quiet Capital. The Wall Street Journal reported a valuation of $3.1 billion, triple the figure from just a year ago. In its funding announcement, NewLimit revealed that following breakthrough research results, the company is advancing its longevity medicine into human clinical trials, with its first drug targeting alcohol-related liver disease expected to enter trials next year.
From Crypto Empire to Life Science: Brian Armstrong’s Bet
NewLimit’s co-founder is none other than Coinbase CEO Brian Armstrong. In 2021, he teamed up with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel, contributing a combined $110 million to launch the company in South San Francisco. Prior to this round, NewLimit had raised three undisclosed rounds, but the Series C injection significantly beefs up its capital reserves and R&D capacity, underlining Armstrong’s appetite for transformative technology beyond crypto.
The Science: Yamanaka Factors and Epigenetic Reprogramming
NewLimit’s scientific foundation rests on a 2006 Nobel laureate discovery by Japanese scientist Shinya Yamanaka. He demonstrated that by activating just a few specific transcription factors, adult cells could be reprogrammed into an embryonic stem cell-like youthful state—now known as Yamanaka Factors. This overturned the long-standing belief that cellular age is irreversible. NewLimit states: “Our drugs activate specific transcription factor genes to reprogram the epigenome to a younger state. We know reversal is possible, but the exact combination of factors needed for each cell type remains unknown. Identifying these effective payloads is our core challenge.”
The company adds, “By reprogramming cell age, humans can achieve longer healthspans, and we are now closer than ever to slowing or even reversing aging.”
Clinical Strategy: Alcohol-Associated Liver Disease as a Launchpad
To fast-track regulatory approval, NewLimit is targeting a specific disease first. Its lead candidate addresses alcohol-associated liver disease, which co-founder and CEO Jacob Kimmel describes as an “accelerated form of aging” that mirrors the universal aging process but in a faster and more intense manner. This makes it an ideal proving ground for cellular reprogramming therapies. Successful approval will then pave the way for broader aging-related indications.
A Gathering of Billionaires: The Race to Conquer Aging
NewLimit is not alone. In 2022, Sam Altman invested $180 million into Retro Biosciences, which was recently valued at $1.8 billion. Altos Labs, reportedly backed by Jeff Bezos, launched later that year with $3 billion and has since nearly doubled its total funding. Peter Thiel, the lead investor in this round, has repeatedly called death “the greatest enemy of mankind.” The super-wealthy are pouring billions into longevity, driven by a simple calculus: once wealth and power peak, time becomes the only luxury money can’t buy.
The longevity sector is becoming a playground for the tech and financial elite. From Thiel to Altman to Bezos, these titans are deploying enormous capital to breach what may be humanity’s final frontier—aging itself.
